将生化和临床变量与新生物标志物相结合，评估其改善心力衰竭 (HF) 患者管理的潜力。本研究评估了新预后量表巴塞罗那生物心力衰竭风险评分 (BCN) 的预测效用）以及终末期心力衰竭患者的传统评分、心力衰竭生存评分 (HFSS) 和西雅图心力衰竭模型 (SHFM)。我们还调查了与分析人群预后较差相关的其他危险因素。我们对 2018 年至 2021 年间列入心脏移植的 279 名终末期心力衰竭患者进行了前瞻性分析。计算了他们的 BCN、HFSS 和 SHFM。使用市售试剂盒（Human ST-2 ELISA，SunRedBio Technology Co., Ltd.，上海，中国）测量人类致瘤性抑制2（ST2）。患者的中位年龄为56.0（50.0-60.0）岁， 87.1%为男性。在一年的随访期间，95 名患者（34.1%）死亡。与一年死亡率相关的 ROC 面积如下：BCN 为 0.9466 [95% CI：0.9194-0.9737]，HFSS 为 0.8092 [0.7606-0.8578]，SHFM 为 0.6967 [0.6349-0.7585]。 BCN（HR = 0.985 [0.981-0.988]，P <0.001）、HFSS（HR = 0.357 [0.236-0.541]，P <0.001）和循环胆红素浓度（HR = 1.015 [1.002-1.028]，P = 0.02）与分析人群的一年死亡率相关。BCN 风险评分的预后表现明显优于 HFSS 或 SHFM。较低的 BCN 和 HFSS 评分以及较高的胆红素与终末期患者的一年死亡风险较高独立相关。高频阶段。

A combination of biochemical and clinical variables with new biomarkers is evaluated for the potential to improve the management of patients with heart failure (HF).This study assessed the predictive utility of a new prognostic scale, the Barcelona Bio-Heart Failure Risk Score (BCN), as well as traditional scores, the Heart Failure Survival Score (HFSS) and the Seattle Heart Failure Model (SHFM), in patients with end-stage HF. We also investigated the other risk factors associated with worse prognosis in the analyzed population.We performed a prospective analysis of 279 patients with end-stage HF listed for heart transplantation between 2018 and 2021. Their BCN, HFSS and SHFM were calculated. Human suppression of tumorigenicity 2 (ST2) was measured with a commercially available kit (Human ST-2 ELISA, SunRedBio Technology Co., Ltd., Shanghai, China).The median age of the patients was 56.0 (50.0-60.0) years, and 87.1% were male. During the one-year follow-up, 95 (34.1%) patients died. The areas under ROC associated with one-year mortality were as follows: 0.9466 [95% CI: 0.9194-0.9737] for BCN, 0.8092 [0.7606-0.8578] for HFSS, and 0.6967 [0.6349-0.7585] for SHFM. BCN (HR = 0.985 [0.981-0.988], P <0.001), HFSS (HR = 0.357 [0.236-0.541], P <0.001] and circulating bilirubin concentration (HR = 1.015 [1.002-1.028], P = 0.02) were associated with one-year mortality in the analyzed population.The BCN risk score had significantly better prognostic performance than HFSS or SHFM. Lower BCN and HFSS scores and higher bilirubin are independently associated with a higher risk of one-year death in patients with end-stage HF.